Company
Headquarters: Hangzhou, China
CEO: Mr. Lieming Ding
CN¥23.00 Billion
CNY as of Jan. 1, 2025
US$3.15 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. Betta Pharmaceuticals Co., Ltd. was founded in 2003 and is headquartered in Hangzhou, China.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥2.76 B |
| EBITDA | CN¥452.9 M |
| Gross Profit TTM | CN¥2.05 B |
| Profit Margin | 16.67% |
| Operating Margin | 17.02% |
| Quarterly Revenue Growth | 15.70% |
Betta Pharmaceuticals Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300558 wb_incandescent